$3.00
4.46% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US43906K1007
Symbol
HOOK
Sector
Industry

Hookipa Pharma, Inc. Target price 2024 - Analyst rating & recommendation

Hookipa Pharma, Inc. Classifications & Recommendation:

Buy
75%
Hold
25%

Hookipa Pharma, Inc. Price Target

Target Price $41.00
Price $3.00
Potential
Number of Estimates 4
4 Analysts have issued a price target Hookipa Pharma, Inc. 2025 . The average Hookipa Pharma, Inc. target price is $41.00. This is higher than the current stock price. The highest price target is
$50.00 1,566.67%
register free of charge
, the lowest is .
A rating was issued by 4 analysts: 3 Analysts recommend Hookipa Pharma, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Hookipa Pharma, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Hookipa Pharma, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 20.13 40.00
41.26% 98.69%
EBITDA Margin -404.27% -123.42%
17.17% 69.47%
Net Margin -516.60% -204.86%
517.09% 60.34%

3 Analysts have issued a sales forecast Hookipa Pharma, Inc. 2024 . The average Hookipa Pharma, Inc. sales estimate is

$40.0m
Unlock
. This is
20.01% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$53.1m 6.18%
Unlock
, the lowest is
$25.0m 50.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $20.1m 41.26%
2024
$40.0m 98.69%
Unlock
2025
$18.3m 54.16%
Unlock
2026
$11.3m 38.64%
Unlock
2027
$114m 916.84%
Unlock
2028
$298m 160.71%
Unlock

The average Hookipa Pharma, Inc. net profit estimate is

$-81.9m
Unlock
. This is
70.43% lower
Unlock
than the net profit for the last 12 months(TTM).

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-104m 771.72%
2024
$-81.9m 21.21%
Unlock
2025
$-36.2m 55.88%
Unlock

Net Margin

2023 -516.60% 517.09%
2024
-204.86% 60.34%
Unlock
2025
-197.18% 3.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share $ -8.63 -6.80
771.72% 21.21%
P/E negative
EV/Sales negative

The average Hookipa Pharma, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-6.80
Unlock
. This is
70.43% lower
Unlock
than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-8.63 771.72%
2024
$-6.80 21.21%
Unlock
2025
$-3.00 55.88%
Unlock

P/E ratio

Current -0.75 50.00%
2024
-0.44 41.33%
Unlock
2025
-1.00 127.27%
Unlock

Based on analysts' sales estimates for 2024, the Hookipa Pharma, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-0.52
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.42 87.00%
2024
-0.52 23.57%
Unlock
2025
-1.13 118.19%
Unlock
2026
-1.85 62.95%
Unlock
2027
-0.18 90.16%
Unlock
2028
-0.07 61.65%
Unlock

P/S ratio

Current 0.72 60.29%
2024
0.90 25.01%
Unlock
2025
1.97 118.16%
Unlock
2026
3.21 62.96%
Unlock
2027
0.32 90.17%
Unlock
2028
0.12 61.66%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today